Talis Biomedical (TLIS) Stock Statistics & Valuation Metrics

Talis Biomedical has a market cap or net worth of $55.45M. The enterprise value is -$38.15M.

Talis Biomedical has 1,822,820 shares outstanding. The number of shares has decreased by -2.65% in one year.

Talis Biomedical’s return on equity (ROE) is -0.90 and return on invested capital (ROIC) is -72.27%.

The current PE Ratio of Talis Biomedical is -0.22. Talis Biomedical’s PEG ratio is >-0.01.

In the last 12 months, Talis Biomedical had revenue of 412.00K and earned -62.01M in profits. Earnings per share was -34.12.

In the last 12 months, operating cash flow was -40.26M and capital expenditures 23.00K, giving a free cash flow of -40.23M billion.

Talis Biomedical pays an annual dividend of ―, resulting in a dividend yield of ―

Talis Biomedical upcoming earnings date is Nov 12, 2024, TBA Not Confirmed.

Talis Biomedical as a current ratio of 8.86, with Debt / Equity ratio of 38.66%

In the past 12 months, Talis Biomedical has paid 0.00 in taxes.

Talis Biomedical EV to EBITDA ratio is 0.66, with an EV/FCF ratio of 0.81.

Talis Biomedical has $59.87M in cash and marketable securities with $18.80M in debt, giving a net cash position of -$41.07M billion.

Gross margin is -334.82%, with operating margin of -16217.23%, and net profit margin of -15050.24%.

The average price target for Talis Biomedical is ―, which is 11.43% higher than the current price. The consensus rating is ―